Clinical Research & Studies
Xeomin's safety and effectiveness are backed by extensive clinical research and real-world evidence from years of medical use.
FDA Approved
Approved by the FDA for both cosmetic and therapeutic uses with proven safety profile.
Clinical Efficacy
Multiple studies demonstrate significant wrinkle reduction with high patient satisfaction rates.
Unique Purification
Advanced purification process removes unnecessary proteins for potentially better outcomes.
Key Clinical Study Results
Duration: Results typically last 3-4 months
Onset: Visible improvements within 3-4 days
Peak Effect: Full results within 7-14 days
Safety: Well-tolerated with minimal side effects
Efficacy: Significant wrinkle reduction in clinical trials
Satisfaction: High patient satisfaction rates
Clinical Research References
The following peer-reviewed studies demonstrate Xeomin's clinical efficacy and safety profile:
Efficacy Study
Park JY et al. Plast Reconstr Surg Glob Open. 2020:8(1)e2627
Dermatological Assessment
Kerscher M, et al. J Drugs Dermatol. 2019 Jan 1:18(1):52-57
Long-term Safety
Rzany B., et al. Dermatol Surg 2013; 95-103.
Phase III Trial
Imhof M, Kühne U. IncobotulinumtoxinA Phase III Study. 2011; 4(10):28-34
Clinical Intervention
Prager W, et al. Clin Interv Aging. 2013;8:449-56
Cosmetic Investigation
Rappi T, et al. Clin Cosmet Investig Dermatol. 2013; Sep 24: 6:211-19
Dermatologic Surgery
Kane MA, et al. Dermatol Surg. 2015;41(11):1319
Comparative Study
Sattler G, et al. Dermatol Surg 2010;36(Suppl 4):2146–54
Treatment Analysis
Prager W, et al. Dermatol Surg 2010; 36(Suppl 4):2155–60
Recent Research
Fischer T, et al. J Drugs Dermatol. 2020;19(5):461-469
Aesthetic Outcomes
Chao YY, et al. J Clin Aesthet Dermatol. 2019;12(12):E53-E57
Product Information
XEOMIN® Approved Product Information. Aug 2021